KLRA
Kailera Therapeutics Inc. · NASDAQ
- Market cap
- $1.58B
Kailera Therapeutics Inc. (KLRA) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for KLRA, including 2 press releases and news items, 2 SEC filings and 1 earnings update. The most recent was published Nov 10, 2026.
KLRA rankings
News · 26 weeks27+200%
2026-05-242026-11-15
Mix1190d
- Other5(45%)
- Insider2(18%)
- SEC Filings2(18%)
- Earnings1(9%)
- Analyst1(9%)
Activity · 52 weeks5625 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRKailera Therapeutics to Present at ObesityWeek 2026Ribupatide injection Phase 3 KaiNETIC trial design presentations highlight its potential to address diverse needs across the obesity spectrumReal-world obesity management presentation highlights the clinical unmet needs of people living with obesity WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that new clinical and real-world research will be presented at ObesityWeek 2026, taking place November 14-17 in Washington, D.C. The research includes the design of the Phase 3 KaiNETIC trials evaluating ribupatide injection, alongside an
- ANALYSTCanaccord Genuity initiated coverage on Kailera Therapeutics with a new price targetCanaccord Genuity initiated coverage of Kailera Therapeutics with a rating of Buy and set a new price target of $44.00
- SECSEC Form 10-Q filed by Kailera Therapeutics Inc.10-Q - Kailera Therapeutics, Inc. (0002096997) (Filer)
- SECKailera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kailera Therapeutics, Inc. (0002096997) (Filer)
- PRKailera Reports Third Quarter 2026 Financial Results and Provides Business UpdatesRibupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDARibupatide injection Phase 2b trial and KaiNETIC global Phase 3 program fully enrolled; data expected mid-2027 and mid-2028, respectivelySafiglipron (KAI-7535) global Phase 2 trial fully enrolled; data now anticipated mid-2027KAI-4729 IND now active with U.S. FDA; on track to initiate Phase 1 single-dose injection site/ethnic bridging trial by the end of 2026Cash continues to support execution of multiple clinical milestones with runway into mid-2028 WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA) (Kailera), a clinical-stage
- PRKailera Therapeutics to Participate in November Investor ConferencesWALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron Renaud, President and Chief Executive Officer, and additional members of the management team will participate in the following investor conferences: Stifel 2026 Healthcare ConferenceNovember 10-12, 2026, New York, NYPresentation: Tuesday, November 10, 2026, at 4:00 pm ETJefferies Global Healthcare Conference in LondonNovember 16-19, 2026, London, UKFireside Chat: Monday, November 16, 2026, at 10:00 am GMT9th Annual Evercore Healthcare ConferenceNovember 30-December 2, 2026, C
- PRKailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting- New Phase 1 data highlight flexibility of injection site for ribupatide injection - Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced Phase 1 data for ribupatide injection, a GLP-1/GIP receptor dual agonist currently advancing through global Phase 3 clinical trials, presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, partner Hengrui Pharma delivered four oral pres
- PRKailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection- Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher - Topline data now expected in mid-2028 WALTHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the completion of enrollment in the KaiNETIC global Phase 3 clinical program. The KaiNETIC program, which encompasses three trials – KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3 – is evaluating ribupatide injection (also known as KAI-9531), an investigational once-weekly dual GLP-1/GIP receptor agonis
- PRKailera Therapeutics to Participate in September Investor ConferencesWALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced participation in the following investor conferences: Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare ForumWednesday, September 23, 2026, 9:40 a.m. ETFireside Chat with Jamie Coleman, Chief Commercial Officer Stifel 2026 Virtual Cardiometabolic ForumWednesday, September 30, 2026, 11:30 a.m. ETFireside Chat with Ron Renaud, Chief Executive Officer, Doug Pagán, Chief Financial Officer, and Scott Wasserman, Chief Medical Officer The live webcasts will be a
- INSIDERSEC Form 4 filed by Chief Technology Officer Nicholson Nur4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- INSIDERSEC Form 3 filed by new insider Nicholson Nur3 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Kailera Therapeutics Inc.SCHEDULE 13G - Kailera Therapeutics, Inc. (0002096997) (Subject)
- SECSEC Form 10-Q filed by Kailera Therapeutics Inc.10-Q - Kailera Therapeutics, Inc. (0002096997) (Filer)
- SECKailera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kailera Therapeutics, Inc. (0002096997) (Filer)
- PRKailera Reports Second Quarter 2026 Financial Results and Provides Business UpdatesIND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in mid-2027Expanded executive team to strengthen technical operations capabilities and corporate affairs leadershipCash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028 WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for t
- PRKailera Therapeutics Appoints Nur Nicholson as Chief Technology OfficerWALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Nur Nicholson as Chief Technology Officer, effective August 31, 2026. "We are excited to welcome Nur as an executive at such a pivotal moment for Kailera," said Ron Renaud, President and Chief Executive Officer of Kailera. "As we advance ribupatide injection through global Phase 3 trials, look to begin our Phase 3 program for ribupatide oral in the first half of next year, and continue the development of our broader pipeline, Nur’s track record of building resilient
- SECSEC Form SCHEDULE 13G filed by Kailera Therapeutics Inc.SCHEDULE 13G - Kailera Therapeutics, Inc. (0002096997) (Subject)
- INSIDERSEC Form 4 filed by Officer Tregoning Kathleen4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- INSIDERSEC Form 3 filed by new insider Tregoning Kathleen3 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- PRKailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535In Phase 3 trial in obesity/overweight in China, HRS-7535 achieved a mean weight loss of up to 10.9% at Week 44 and a mean weight loss of up to 11.1% at Week 50 Kailera currently conducting global Phase 2 trial of KAI-7535 in obesity to further optimize KAI-7535's clinical profile for the treatment of obesityIn second Phase 3 trial in type 2 diabetes in China, HRS-7535 lowered HbA1c by an average of 1.50% to 1.68% across dosesLiver safety findings in both Phase 3 trials consistent with data generated to date; no liver safety signals observed WALTHAM, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Kailera), a clinical-stage biotechnology company focused on elevating t
- PRKailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs OfficerWALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer. "We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape," said Ron Renaud, President and Chief Executive Officer of Kailera. "Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic per
- INSIDERCEO & President Renaud Ronald C Jr exercised 38,094 shares at a strike of $5.25 (SEC Form 4)4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- PRHengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweightAdditional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with vomiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectivelyPhase 1 single ascending dose trial, the first ribupatide injection clinical data generated outside of China
- PRKailera Therapeutics to Present at the 2026 Jefferies Global Healthcare ConferenceWALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron Renaud, President and Chief Executive Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, at 10:30 am EDT. A live webcast will be available on the Events page of Kailera's investor website. A replay of the conference webcast will be archived on the company's website for 90 days. About Kailera Therapeutics Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a
- SECSEC Form 10-Q filed by Kailera Therapeutics Inc.10-Q - Kailera Therapeutics, Inc. (0002096997) (Filer)
KLRA FAQ
7 questionsWhat is the latest news on KLRA?
In the last 30 days Quantisnow tracked 6 wire items for KLRA: 2 press releases and news items, 2 SEC filings, 1 earnings update and 1 analyst rating. The most recent was published on November 10, 2026.Where does KLRA stock trade?
Kailera Therapeutics Inc. (KLRA) is listed on NASDAQ.What sector and industry is KLRA in?
Kailera Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Kailera Therapeutics Inc. go public?
Kailera Therapeutics Inc. (KLRA) completed its IPO in 2026.What are analysts saying about KLRA?
Kailera Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $44.00 price target on 2026-11-09. Recent price targets range from $30.00 to $57.00.What companies are similar to KLRA?
Notable peers in the same industry include MRK (Merck & Company Inc.), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S), ABT (Abbott Laboratories), JNJ (Johnson & Johnson). Compare KLRA side-by-side with any of them on Quantisnow.How can I track KLRA on Quantisnow?
Quantisnow aggregates Kailera Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KLRA to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change